Literature DB >> 428189

Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms.

N L Benowitz, J Rosenberg, W Rogers, J Bachman, R T Jones.   

Abstract

The contribution of autonomic nervous system activity to the cardiovascular effects of delta-9-tetrahydrocannabinol (THC) was evaluated in 4 normal subjects. The peak heart rate rise after THC was attenuated by atropine and by propranolol, and nearly abolished by atropine-propranolol pretreatment. Blocking drugs also attenuated THC-induced changes in forearm blood flow and vascular resistance but did not affect changes in fingertip temperature. The data suggest that THC acts to induce sympathetic stimulation and parasympathetic inhibition of cardiovascular control pathways. Cardiovascular responses in an additional subject who developed hypertension after either intravenous or smoked marijuana are described.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 428189     DOI: 10.1002/cpt1979254440

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Enhancement of rostral ventrolateral medulla neuronal nitric-oxide synthase-nitric-oxide signaling mediates the central cannabinoid receptor 1-evoked pressor response in conscious rats.

Authors:  Badr Mostafa Ibrahim; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2012-02-24       Impact factor: 4.030

3.  Safety of oral dronabinol during opioid withdrawal in humans.

Authors:  Crystal J Jicha; Michelle R Lofwall; Paul A Nuzzo; Shanna Babalonis; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

4.  Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.

Authors:  Emma Childs; Joseph A Lutz; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2017-05-30       Impact factor: 4.492

5.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

6.  Role of brainstem GABAergic signaling in central cannabinoid receptor evoked sympathoexcitation and pressor responses in conscious rats.

Authors:  Badr Mostafa Ibrahim; Abdel A Abdel-Rahman
Journal:  Brain Res       Date:  2011-07-28       Impact factor: 3.252

7.  Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats.

Authors:  James R Padley; Qun Li; Paul M Pilowsky; Ann K Goodchild
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

8.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

9.  Tolerability and effects of oral Delta9-tetrahydrocannabinol in older adolescents with marijuana use disorders.

Authors:  Kevin M Gray; Carl L Hart; Douglas K Christie; Himanshu P Upadhyaya
Journal:  Pharmacol Biochem Behav       Date:  2008-06-26       Impact factor: 3.533

10.  Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.

Authors:  Allan J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.